Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

Background Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). Objectives We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. Materials and methods A retrospec...

Full description

Bibliographic Details

Published in:	Journal of neurology Vol. 266; no. 2; pp. 411 - 416
Main Authors:	D’Amico, E., Zanghì, A., Sciandra, M., Borriello, G., Callari, G., Gallo, A., Salemi, G., Cottone, S., Buccafusca, M., Valentino, P., Bossio, R. B., Grimaldi, L. M. E., Pozzilli, C., Tedeschi, G., Zappia, M., Patti, F.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2019 Springer Nature B.V
Subjects:	Magnetic resonance imaging Medicine Medicine & Public Health Multiple sclerosis Neurology Neuroradiology Neurosciences Original Communication Population Teriflunomide Discontinuation rate Multiple sclerosis Real-life Dimethyl fumarate
ISSN:	0340-5354, 1432-1459, 1432-1459
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!